• INVESTOR RELATIONS
    • Investor Overview
    • Stock Information
    • Corporate Governance
    • Events & Presentations
    • Financials & Filings
    • Investor Resources
    • Email Alerts
    • News and Media
  • CONTACT US
  • 中文
  • WHO WE ARE
    • ABOUT Zai Lab
    • EXECUTIVE TEAM
    • BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD
    • OUR MISSION
  • WHAT WE DO
    • DISCOVERY
    • DEVELOPMENT
    • MANUFACTURING
    • COMMERCIALIZATION
    • PARTNERING
  • OUR R&D
    • PIPELINE
    • SELECTED ONGOING CLINICAL TRIALS
  • PRODUCTS
  • CAREERS
    • WORKING AT Zai Lab
    • JOIN US
  • NEWS
    • PRESS RELEASE
    • PARTNER NEWS
    • MEDIA REPORTS
    • Email Alerts

  • Innovation for patients with
    unmet medical needs worldwide

    READ MORE

  • More time for more women

    READ MORE

  • Using Tumor Treating Fields
    to fight cancer

    READ MORE

  • Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China

    July 02, 2019

  • Zai Lab Announces Approval to Commercialize ZEJULA (Niraparib) in Macau for Patients with Relapsed Ovarian Cancer

    June 12, 2019

  • Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China

    June 11, 2019

  • About Zai Lab

    Find out more

  • Executive Team

    Find out more

  • Our Mission

    Find out more

  • Pipeline

  • Products

  • Partnering

Copyright @ 2019 Zai Lab All Rights Reserved.